Table 1.
Patient characteristics and demographics
| All patients (n = 34) |
Trametinib/HCQ (n = 19) |
Trametinib/ Palbociclib (n = 15) |
||
|---|---|---|---|---|
| Age, years | 62 (32–81) | 61 (32–81) | 63 (43–70) | |
| Sex, n (%) | ||||
| Male | 25 (73.5%) | 13 (68.4%) | 12 (80%) | |
| Female | 9 (26.5% | 6 (31.6%) | 3 (20%) | |
| Previous treatment lines, median (range) | 3 (1–7) | 3 (2–7) | 2 (1–6) | |
| 1 previous treatment line, n (%) | 2 (5.9%) | 0 (0%) | 2 (13.3%) | |
| 2 previous treatment lines, n (%) | 14 (41.2%) | 5 (26.3%) | 9 (60%) | |
| 3 previous treatment lines, n (%) | 8 (23.5%) | 7 (36.8%) | 1 (6.7%) | |
| 4 previous treatment lines, n (%) | 4 (11.8%) | 3 (15.8%) | 1 (6.7%) | |
| > 4 previous treatment lines, n (%) | 6 (17,7%) | 4 (21.1%) | 2 (13.3%) | |
| Median ECOG PS | 1 | 1 | 1 | |
| ECOG 0, n (%) | 4 (11.8% | 2 (10.5%) | 2 (13.3%) | |
| ECOG 1, n (%) | 21 (61.8%) | 13 (68.4%) | 8 (53.3%) | |
| ECOG 2, n (%) | 4 (11.8%) | 0 (0%) | 4 (26.7%) | |
| n.a., n (%) | 5 (14.7% | 4 (21.1%) | 1 (6.7%) | |
| UICC stage | ||||
| UICC IV, n (%) | 33 (97.1%) | 18 (94.7%) | 15 (100%) | |
| n.a., n (%) | 1 (2.9%) | 1 (5.3%) | 0 (0%) | |
| KRAS status | ||||
| KRAS mutated, n (%) | 34 (100%) | 19 (100%) | 15 (100%) | |
| CDKN2A status | ||||
| CDKN2A alteration/loss, n (%) | 16 (47.1%) | 1 (5.3%) | 15 (100%) | |
| CDKN2A wt, n (%) | 10 (29.4%) | 10 (52.6%) | 0 (0%) | |
| n.a., n (%) | 8 (23.5%) | 8 (42.1%) | 0 (0%) | |